¡Ya estamos en ! Descubre más

Biofrontera

BFRI

Capitalización de mercado USD 12.2 M

0.8216 USD

-0.0255

3.01%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

0.8200

-0.0016

0.19%

1 día

-3.01%

5 días

-15.54%

1 mes

-32.1%

3 meses

-25.98%

6 meses

-23.93%

En lo que va del año

13.32%

1 año

-17.01%

5 años

-99.07%

10 años

-99.07%

Acerca de: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Empleados: 94

Atención médica Fabricantes de medicamentos especializados y genéricos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 100%

Negativo 0%

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript

Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript

Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.

Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™